Current Report Filing (8-k)
July 12 2017 - 8:41AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of
Report (date of Earliest Event Reported): JULY 6, 2017
moleculin
biotech, INC.
(Exact Name of Registrant as Specified in
its Charter)
|
DELAWARE
|
001-37758
|
47-4671997
|
|
(State or Other Jurisdiction of Incorporation or Organization)
|
(Commission File No.)
|
(I.R.S. Employer Identification No.)
|
2575
WEST BELLFORT, SUITE 333, HOUSTON TX 77054
(Address of principal executive offices
and zip code)
(713) 300-5160
(Registrant’s telephone number, including
area code)
(Former name or former address, if changed
from last report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(
see
General Instruction A.2. below):
¨
Written communications pursuant to
Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule
14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant
to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c)).
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
x
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.
x
Item 8.01 Other Events.
As previously reported,
on May 18, 2017, Moleculin Biotech, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications
Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that for the last
30 consecutive business days the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement
for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”).
In accordance with
Nasdaq Listing Rule 5810(c)(3)(A) (the “Compliance Period Rule”), the Company was provided 180 calendar days, or until
November 14, 2017 (the “Compliance Date”), to regain compliance with the Bid Price Rule. To regain compliance with
the Bid Price Rule, before the Compliance Date, the bid price for the Company’s common stock needed to close at $1.00 or
more for a minimum of 10 consecutive business days.
On July 6, 2017, the
Company received a letter from NASDAQ notifying the Company that it had regained compliance with NASDAQ Listing Rule 5550(a)(2)
as a result of the closing bid price of the Company’s common stock being at $1.00 per share or greater for the 10 consecutive
business days from June 21, 2017 through July 5, 2017.
Accordingly, the Company
is in compliance with the Bid Price Rule and NASDAQ considers the matter closed.
SIGNATURE
Pursuant to the requirements
of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
MOLECULIN BIOTECH, INC.
|
|
|
|
|
|
|
|
Date: July 12, 2017
|
|
|
|
By:
|
/s/ Jonathan Foster
|
|
|
|
Jonathan Foster
|
|
|
|
Chief Financial Officer
|
Moleculin Biotech (NASDAQ:MBRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Moleculin Biotech (NASDAQ:MBRX)
Historical Stock Chart
From Apr 2023 to Apr 2024
